Not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or within the United States, Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of South Africa or any other jurisdiction where it is unlawful to distribute this announcement.
Verici Dx plc
("Verici Dx" or the "Company")
Successful Restricted Offer
Update on Fundraising and Admission
Capitalised terms in this announcement carry the same definitions
as in prior announcements in relation to the Fundraising.
Verici Dx plc, a developer of advanced clinical diagnostics for organ transplant, announces the result of the Restricted Offer made to its shareholders, who returned a valid application form to subscribe for Verici Dx Ordinary Shares of £0.001 each ("Verici Shares") at the Issue Price, being 20 pence per share (the "Restricted Offer").
The Restricted Offer for up to £0.5 million was significantly oversubscribed as expected.
The Placing, Subscription and Restricted Offer have, in aggregate, raised £14.5 million through the issue of a total of 72,500,000 new Ordinary Shares at the Issue Price.
The allotment and issue of Verici Dx Shares in connection with the Restricted Offer remains conditional upon, among other things, Admission, which is expected to take place on 3 November.
Applicants to the Restricted Offer can confirm their final allotment of shares by contacting the helpline on 0371 664 0321. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. The helpline is open between 9.00 a.m. and 5.30 p.m., Monday to Friday excluding public holidays in England and Wales. Different charges may apply to calls from mobile telephones and calls may be recorded and randomly monitored for security and training purposes. The helpline cannot provide advice on the merits of the Proposals nor give any financial, legal or tax advice.
Full details of the Fundraising will be contained in the Verici Dx Admission Document, which will be made available shortly before Admission at www.vericidx.com
Enquiries:
| Verici Dx |
||
| Sara Barrington, CEO |
Via Walbrook PR |
|
| Julian Baines, Chairman |
|
|
| |
|
|
| N+1 Singer (Nominated Adviser & Broker) |
Tel: 020 7496 3000 |
|
| Aubrey Powell / Justin McKeegan (Corporate Finance)
|
|
|
| Walbrook PR Limited |
Tel: 020 7933 8780 or vericidx@walbrookpr.com |
|
| Paul McManus / Sam Allen |
Mob: 07980 541 893 / 07748 651 727 |
|
About Verici Dx plc
Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney. One of the most significant threats to a successful transplant, or graft, is the body's own immune system. Patients' immune systems differ in how they respond to the presence of the transplanted organ; characterizing this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and, ultimately, failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.